Your Messages Inbox
Your Article Summary
See Latest ArticlesMedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza
Medimmune, 09/22/09
MedImmune announced that the U.S. Department of Health and Human Services has placed an order for an additional 29 million doses of its live attenuated influenza vaccine against the 2009 H1N1 influenza virus. This brings HHS orders to date to more than 40 million vaccine doses, with a total cumulative contract value of approximately $453 million. Previous HHS orders for approximately 13 million doses of LAIV for the 2009 H1N1 strain were placed in May and July. The vaccine received approval from the U.S. Food and Drug Administration (FDA) on Sept. and is indicated for the active immunization of individuals 2–49 years of age against influenza caused by pandemic 2009 virus.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/08/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Cerner Enters R&D Pact with University
HealthDataManagement, 12/08/09
ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
ARIAD Pharmaceuticals, 12/08/09
Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multiple Myeloma
Bristol Myers-Squibb Company, 12/08/09
Article Search
Sponsor